SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
A man is holding an umbrella while standing on a cliff. The umbrella is green and the man is looking up at the sky. Concept of danger and uncertainty, as the man is on the edge of a cliff
Bankruptcy
Gritstone Files for Bankruptcy in Effort to Save Clinical Research
Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the company hopes will save its clinical research in cancer and infectious disease.
October 10, 2024
 · 
1 min read
 · 
Annalee Armstrong
Pictured: Astellas' Americas headquarters in Illin
Layoffs
Astellas Cuts 24 Universal Cells Roles in Seattle, Transfers 12 to Japan
Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.
October 10, 2024
 · 
1 min read
 · 
Angela Gabriel
Drug Development
How AI Could Ease Tension in Clinical Trials
In the third episode of our mini series on artificial intelligence, Lori and guests continue their exploratory discussion on AI and the opportunity in patient lives.
October 10, 2024
 · 
1 min read
 · 
Lori Ellis
Sign in front of Pfizer in Quebec, Canada
Prostate cancer
Pfizer Phase III Prostate Cancer Win Builds Case for Broader Label for Talzenna-Xtandi Combo
The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, potentially covering all patients with metastatic castration-resistant prostate cancer regardless of biomarker status.
October 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Concept art of a gene therapy showing a syringe injecting into a 3D DNA helix
Gene therapy
7 Children Receiving Bluebird’s Gene Therapy Developed Blood Cancers: Study
The pediatric patients, with a rare neurodegenerative disease, were treated with bluebird bio’s Skysona to slow the progression of neurologic dysfunction. Six patients developed myelodysplastic syndrome and one patient developed acute myeloid leukemia.
October 10, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's headquarters office building in Poznan, Poland
Legal
GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer. Analysts say separate concerns remain about its vaccines business.
October 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Photo of Carlos Doti, vice president and head of medical affairs for the U.S. oncology business unit at AstraZeneca
People
From Argentina to America: A Physician’s Journey to Pharma and AstraZeneca
Carlos Doti has moved countries and changed jobs, but one thing hasn’t changed. Making an impact on patient care has always been a priority for the AstraZeneca executive.
October 10, 2024
 · 
6 min read
 · 
Angela Gabriel
Man inside a boat made with a dollar
M&A
Concentra Spies New Target After Kezar’s Lupus Trial Hold
After four patient deaths, Kezar’s lupus trial is officially on hold, sparking investor Kevin Tang’s interest for acquisition.
October 9, 2024
 · 
1 min read
 · 
Kate Goodwin
Matthew Durdy, chief executive of the Cell and Gene Therapy Catapult, speaks at 2024 Meeting on the Mesa at a session also involving (left to right) Pfizer’s Bert Bruce, Bayer Nuno Fontes’, BMS’ Magdalene Pedersen and Eli Lilly’s Manny Simons.
Cell and gene therapy
Big Pharma’s Interest Grows in Evolving Cell and Gene Therapy Sector
Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.
October 9, 2024
 · 
4 min read
 · 
Greg Slabodkin
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS